财说|一桩交易重构双抗药物市场,康方生物为何“受伤”?

界面
30 May

上周三生国健(688336.SH)连续三个交易日涨停,5月19日至今涨幅超过85%。引发市场关注的重要信息是三生国健及关联方沈阳三生与辉瑞(Pfizer Inc.)签署了关于SSGJ-707项目(双靶点PD-1/VEGF抗体)的全球开发、生产和商业化独家授权协议。本次交易首付款为12.5亿美元,总潜在交易金额达60.5亿美元,若按当日汇率折算超过430亿元人民币,刷新国产双抗出海交易金额纪录。也...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10